DMAA

Drugs Made In America Acquisition Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↓ 2/10
  • Value↑ 7/10
Drugs Made In America Acquisition sales and earnings growth
DMAA Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 733.33%
  • FCF Y/Y↓ -213.00%
Drugs Made In America Acquisition gross and profit margin trends
DMAA Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Drugs Made In America Acquisition net debt vs free cash flow
DMAA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Drugs Made In America Acquisition stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Shell Companies stocks